Sun Pharma Agreed to Pay $11.75 Billion for Organon. The Portfolio Is Women's Health. The Thesis Is Not.
📕Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #3 on Amazon hot new releases in our category. Will you help me make it to #1?
The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar manufacturer. Here is what that means for where the exits go from here.
What happened
On 26 April 2026, Sun Pharmaceutical Industries signed a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion. The offer price of $14 per share represents a 24% premium to Organon’s closing price the previous Friday. The deal is the largest overseas acquisition in Indian pharmaceutical history.
The transaction transfers Organon’s full portfolio to Sun: Nexplanon, the world’s leading contraceptive implant; NuvaRing; Follistim for fertility; and a biosimilar portfolio including Hadlima and Renflexis. It also transfers Organon’s commercial infrastructure in China, where the company generates more than $800 million in annual revenue.
Combined, the two entities are projected to generate approximately $12.4 billion in revenue, placing the merged group among the 25 largest pharmaceutical companies globally.
Sun Pharma anticipates becoming a top-three global player in women’s health and the seventh-largest biosimilar company worldwide. The deal is expected to close in early 2027, pending regulatory approvals and shareholder consent.